Global Hepatology Market Size to Worth USD 43.65 Billion by 2033 | CAGR of 11.60%

Category: Healthcare

RELEASE DATE Mar 2024
REPORT ID SI3950

A PHP Error was encountered

Severity: Notice

Message: Undefined variable: table

Filename: press/detail.php

Line Number: 118

Backtrace:

File: /home/admin/web/sphericalinsights.com/public_html/application/views/press/detail.php
Line: 118
Function: _error_handler

File: /home/admin/web/sphericalinsights.com/public_html/application/views/layouts/master_header_footer.php
Line: 702
Function: view

File: /home/admin/web/sphericalinsights.com/public_html/application/controllers/Press.php
Line: 89
Function: view

File: /home/admin/web/sphericalinsights.com/public_html/index.php
Line: 295
Function: require_once

Global Hepatology Market worth USD 43.65 Billion by 2033

According to a research report published by Spherical Insights & Consulting, the Global Hepatology Market Size is to grow from USD 14.57 Billion in 2023 to USD 43.65 Billion by 2033, at a Compound Annual Growth Rate (CAGR) of 11.60% during the projected period.        

 

Global Hepatology Market

Get more details on this report -

Request Free Sample PDF

 

Browse key industry insights spread across 200 pages with 110 Market data tables and figures & charts from the report on the " Global Hepatology Market Size, Share, and COVID-19 Impact Analysis, By Treatment Type (Antiviral Drugs, Vaccines, Immunosuppressants, Targeted Therapy, Chemotherapy, Corticosteroids, Immunoglobulins), By Disease Type (Hepatitis, Liver Cancer, Genetic Disorders, Autoimmune Diseases, Non- Alcoholic Fatty Liver Diseases, Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033." Get Detailed Report Description Here:https://www.sphericalinsights.com/reports/hepatology-market        

 

The hepatology market focuses on liver-related diseases and conditions. It includes conditions such as hepatitis, liver cirrhosis, fatty liver disease, and liver cancer. The global hepatology market is expanding rapidly due to factors such as the rising prevalence of increased awareness of liver health, liver disorders, and improved diagnostic methods. Chronic liver disease is typically caused by excessive alcohol consumption, aflatoxin exposure, and certain genetic conditions. Furthermore, major players in the global hepatology market are investing in R&D to create new treatments and therapies for liver-related diseases. Antiviral medications for hepatitis, immunosuppressants for autoimmune liver diseases, and new therapies for conditions like NAFLD all contribute significantly to the hepatology market. Collaborations between pharmaceutical companies, academic institutions, and research organizations also contribute to the development of a strong pipeline of innovative therapies. However, patients with financial constraints are less likely to receive necessary therapy when drugs and treatments are expensive due to high manufacturing costs. Some patients might need assistance to continue to afford their prescribed prescriptions.

 

The antiviral drugs segment is expected to hold the greatest share of the global hepatology market during the projected timeframe. 

Based on the treatment type, the global hepatology market is divided into antiviral drugs, vaccines, immunosuppressants, targeted therapy, chemotherapy, corticosteroids, and immunoglobulins. Among these, the antiviral drugs segment is expected to grow at hold the greatest share in the global hepatology market during the projected timeframe. Antiviral medications, including nucleoside/nucleotide analogs and direct-acting antivirals (DAAs), have become standard treatments for viral hepatitis. Several factors contribute to the high demand for antiviral medications.

 

The hepatitis segment is expected to hold the greatest share of the global hepatology market during the projected timeframe.     

Based on the disease type, the global hepatology market is divided into hepatitis, liver cancer, genetic disorders, autoimmune diseases, non-alcoholic fatty liver diseases, and others. Among these, the hepatitis segment is expected to hold the greatest share of the global hepatology market during the projected timeframe.  Hepatitis affects a large portion of the global population. Chronic hepatitis infections can result in serious liver complications, including cirrhosis and hepatocellular carcinoma. Furthermore, the high prevalence of hepatitis infections, particularly B and C, requires comprehensive diagnostic, treatment, and management strategies.

 

North America is anticipated to hold a significant share of the global hepatology market over the predicted timeframe.

 

North America

Get more details on this report -

Request Free Sample PDF

North America is projected to hold a significant share of the global hepatology market over the predicted timeframe. North America has a robust ecosystem for medical research and development. The region is home to major pharmaceutical and biotechnology companies, as well as academic institutions and research organizations focused on advancing hepatology. Ongoing research initiatives contribute to the development of new therapies, diagnostics, and treatment strategies.

 

Asia-Pacific is predicted to grow at the fastest pace in the global hepatology market during the projected timeframe. The prevalence of liver diseases in Asia-Pacific has grown, requiring the use of hepatology treatments and pharmaceuticals. These diseases include alcoholic liver disease, viral hepatitis, and non-alcoholic fatty liver disease (NAFLD). Improved medical technology and liver disease treatments have propelled the industry forward.

 

Major vendors in the global Hepatology market are Astellas Pharma Inc., AbbVie Inc., Zydus Lifesciences, Bristol-Myers Squibb Company, Takeda Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Emergent BioSolutions Inc., F. Hoffmann- La Roche AG, Eli Lilly and Company, Viatris Inc., Gilead Sciences, Inc., Merck & Co. Inc., Abbott Laboratories, Inc., and Others.

 

Key Target Audience

  • Market Players
  • Investors
  • End-users
  • Government Authorities 
  • Consulting And Research Firm
  • Venture capitalists
  • Value-Added Resellers (VARs)

 

Recent Developments

  • In January 2022, Takeda and Arrowhead Pharmaceuticals Inc. announced key findings from the Phase 2 SEQUOIA clinical trial, which shed light on the efficacy of investigational Fazirsiran in treating liver disease caused by alpha-1 antitrypsin deficiency (AATD-LD).

 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the Global Hepatology Market based on the below-mentioned segments:

 

Global Hepatology Market, Treatment Type Analysis

  • Antiviral Drugs
  • Vaccines
  • Immunosuppressants
  • Targeted Therapy
  • Chemotherapy
  • Corticosteroids
  • Immunoglobulins

 

Global Hepatology Market, Disease Type Analysis

  • Hepatitis
  • Liver Cancer
  • Genetic Disorders
  • Autoimmune Diseases
  • Non- Alcoholic Fatty Liver Diseases
  • Others

 

Global Hepatology Market, Regional Analysis

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • Uk
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • Qatar
    • South Africa
    • Rest of the Middle East & Africa

 

About the Spherical Insights & Consulting

Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.

Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements. 

 

CONTACT US:

For More Information on Your Target Market, Please Contact Us Below:    

Phone: +1 303 800 4326 (the U.S.)

Phone: +91 90289 24100 (APAC)

Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com

Contact Us: https://www.sphericalinsights.com/contact-us

Follow Us: LinkedIn | Facebook | Twitter

Need help to buy this report?

Inquiry Before Buy
We'll use cookies to improve and customize your experience if you continue to browse. Is it OK if we also use cookies to show you personalized ads?
Learn more and manage your cookies
Yes, Accept Cookies